Pfizer Inc
PFE- Latest Trade
- trading lower38.59USD
- -0.06
- 0.17%
- As of Jun 6 2023. Values delayed up to 15 minutes
- Today's Range
- 38.38 - 38.86
- 52 Week Range
- 36.17 - 54.93
- Previous Close
- 38.65
- Open
- 38.81
- Volume
- 7,901,843.00
- 3 Month Average Trading Volume
- 516.86
- Shares Out (Mil)
- 5,645.31
- Market Cap
- 218,191.10
- Forward P/E
- 11.55
- Dividend Yield
- 4.24
Key Statistics
2.42 mean rating - 26 analysts
- P/E Excl. Extra Items (TTM)
- 7.62
- Price To Sales (TTM)
- 2.35
- Price To Book (Quarterly)
- 2.16
- Price To Cash Flow (Per Share TTM)
- 6.34
- Total Debt/Total Equity (Quarterly)
- 35.55
- Long Term Debt/Equity (Quarterly)
- 31.40
- Return On Investment (TTM)
- 19.19
- Return On Equity (TTM)
- 15.33
2021 (millions USD)
About Pfizer Inc (PFE)
Company Information
Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operates through two segments: Biopharma and PC1. Biopharma is engaged in the science-based biopharmaceutical business. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. The Company’s primary care products include Eliquis, Nurtec ODT/Vydura and the Premarin family; the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac and Trumenba; Comirnaty, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Eucrisa/Staquis and Cibinqo; the Vyndaqel family, Oxbryta, BeneFIX and Genotropin, and Sulperazon, Medrol, Zavicefta, Zithromax, Vfend and Panzyga. Its oncology products include Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena and Braftovi.
Address
66 HUDSON BOULEVARD EASTNEW YORK, NY
10001-2192
United States
Industry
Biotechnology & Drugs
Executive Leadership
- Albert Bourla
- Chairman of the Board, Chief Executive Officer
- David M. Denton
- Executive Vice President, Chief Financial Officer
- Angela Hwang
- Chief Commercial Officer, President, Global Biopharmaceuticals Group
- Payal Sahni
- Executive Vice President, Chief People Experience Officer
- Lidia Fonseca
- Executive Vice President, Chief Digital and Technology Officer
- Rady A. Johnson
- Executive Vice President, Chief Compliance, Quality and Risk Officer
- Douglas M. Lankler
- Executive Vice President, General Counsel
- Aamir Malik
- Executive Vice President, Chief Business Innovation Officer
- Michael Mcdermott
- Executive Vice President, Chief Global Supply Officer
- William Pao
- Executive Vice President, Chief Development Officer,
- Sally Susman
- Executive Vice President, Chief Corporate Affairs Officer
- Mikael G. Dolsten
- Chief Scientific Officer, President - Worldwide Research, Development and Medical
- Shantanu Narayen
- Lead Independent Director
- Ronald E. Blaylock
- Independent Director
- Susan Desmond-Hellmann
- Independent Director
- Joseph J. Echevarria
- Independent Director
- Scott Gottlieb
- Independent Director
- Helen H. Hobbs
- Independent Director
- Susan J. Hockfield
- Independent Director
- Dan R. Littman
- Independent Director
- Suzanne Nora Johnson
- Independent Director
- James R. Quincey
- Independent Director
- James Clifton Smith
- Independent Director
Financials
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,961.30 | 0.17% |
| Copper | 721.20 | 0.01% |
| Brent Crude Oil | 76.29 | 0.55% |
| CBOT Soybeans | 1,355.75 | 0.43% |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 4,281.73 | 0.19% |
| Euro STOXX 50 | 4,295.22 | 0.05% |
| FTSE 100 | 7,628.10 | 0.37% |
| Nikkei 225 | 32,506.78 | 0.90% |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes